Goldman Sachs Group Inc Pacira Bio Sciences, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,308,901 shares of PCRX stock, worth $32.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,308,901
Previous 1,104,796
18.47%
Holding current value
$32.5 Million
Previous $27.5 Million
13.94%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding PCRX
# of Institutions
256Shares Held
51.5MCall Options Held
289KPut Options Held
130K-
Black Rock Inc. New York, NY8.01MShares$199 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$134 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.4MShares$59.4 Million0.08% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.25MShares$55.9 Million0.04% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.15MShares$53.4 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.14B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...